Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Pharmacogenomics J. 2011 May 24;12(5):417–424. doi: 10.1038/tpj.2011.18

Table 1.

Summary of Inclusion and Exclusion criteria.

Inclusion criteria Exclusion criteria
Elective hip or knee arthroplasty (not hip fracture) Currently taking warfarin
≥65 years of age Incarcerated or institutionalized
Has Medicare Part B Thrombocytopenia (platelets < 75K)
Warfarin prophylaxis anticipated for at least 4 weeks History of venous thromboembolism
Reliable telephone access History of thrombophilia
Willing to give consent (English only) History of major bleeding or bleeding disorder (e.g. hemophilia, von Willebrand disease, etc.)
Willing/able to have Doppler Ultrasound at 4–6 week follow-up visit Planned administration of any anticoagulant other than warfarin (except heparin flushes)
Baseline INR <1.35 Warfarin genotypes or prior therapeutic warfarin dose known
Life expectancy >6 months Warfarin allergy
Unlikely to be compliant (e.g. history of non-compliance, substance abuse, etc.)
First degree relative with VTE before age 50
Planned administration of interacting medications, except those taken into account by WarfarinDosing.org*
Alcoholism not in remission for past 6 months
*

carbamazepine, rifampin, barbiturates, phenytoin